Skip to main content
OpenTrials

Clinical trial condition

Myeloproliferative Disorders

Explore clinical trials studying Myeloproliferative Disorders. Study availability and eligibility vary by location and protocol.

1,107 public trials 145 recruiting studies
Refine in advanced search Browse all conditions

Myeloproliferative Disorders trial results

Active, Not Recruiting

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, +7 more
Locations
  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 3496) Glendale, Arizona, United States
  • Los Angeles Cancer Network ( Site 3491) Glendale, California, United States
  • Stanford Cancer Institute ( Site 0107) Stanford, California, United States
  • The Lundquist Institute ( Site 3423) Torrance, California, United States
View all 163 locations
View Trial Details
Active, Not Recruiting

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers Chandler, Arizona, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • USC/Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 156 locations
View Trial Details
Active, Not Recruiting

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, +7 more
Locations
  • Palo Verde Cancer Specialists ( Site 0052) Glendale, Arizona, United States
  • Los Angeles Cancer Network ( Site 0025) Glendale, California, United States
  • Stanford Cancer Center ( Site 0024) Palo Alto, California, United States
  • Exempla Lutheran Medical Center ( Site 0014) Golden, Colorado, United States
View all 171 locations
View Trial Details
Active, Not Recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

NCT03516279

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, +15 more
Locations
  • Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • Mercy Hospital Fort Smith Fort Smith, Arkansas, United States
View all 291 locations
View Trial Details
Active, Not Recruiting

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

NCT03817398

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, +12 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • USA Health Strada Patient Care Center Mobile, Alabama, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 173 locations
View Trial Details
Active, Not Recruiting

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

NCT02530034

Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Crisis, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, +31 more
Locations
  • Augusta University Augusta, Georgia, United States
  • Montefiore Medical Center, Albert Einstein College of Medicine The Bronx, New York, United States
  • M D Anderson Cancer Center Houston, Texas, United States
  • Huntsman Cancer Institute Salt Lake City, Utah, United States
View Trial Details
Active, Not Recruiting

Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis

NCT04217356

Conditions
Bone Marrow Cancer, Bone Marrow Diseases, Bone Marrow Neoplasms, +9 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • St. Paul's Hospital Vancouver, British Columbia, Canada
  • Nova Scotia Health Authority Halifax, Nova Scotia, Canada
View Trial Details

Related conditions